Angelman Syndrome (AS) is a complex genetic disorder, which primarily affects the nervous system. The characteristic features of this disease include delayed development, intellectual disability, severe speech impairment, and problems with movement and balance (ataxia).
&nbsp;
Angelman Syndrome Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Angelman Syndrome in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Prevalent cases of Angelman Syndrome</li>
<li>Diagnosed Prevalent Cases of Angelman Syndrome</li>
<li>Angelman Syndrome Cases by Mutation Types</li>
<li>Angelman Syndrome associated with Clinical Manifestations</li>
</ul>
&nbsp;
Angelman Syndrome&nbsp;Epidemiology&nbsp;
<ul>
<li>Total prevalent cases of Angelman Syndrome in 7 MM in 2017 was 57,716&nbsp;&nbsp;</li>
<li>The prevalence of Angelman Syndrome in the United States in 2017 was 21,715&nbsp;&nbsp;</li>
<li>The prevalence of Angelman Syndrome in Germany was 6,448 in 2017&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0066cc;" href="https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast" target="_blank" rel="noopener noreferrer">Angelman Syndrome&nbsp;Market</a>
The therapeutic market of Angelman Syndrome in 7MM in 2017 was USD 255 Million.&nbsp;&nbsp;
&nbsp;
Angelman Syndrome&nbsp;Market Drivers&nbsp;
<ul>
<li>Biomarker Studies</li>
<li>Increasing Prevalence of Angelman Syndrome</li>
<li>Molecular Level Diagnosis</li>
</ul>
&nbsp;
Angelman Syndrome&nbsp;Market Barriers
<ul>
<li>Lack of awareness</li>
<li>Lack of late-stage clinical trials</li>
<li>Lack of Data</li>
<li>Economic Burden</li>
</ul>
&nbsp;
Angelman Syndrome&nbsp;Emerging Drugs
Angelman Syndrome Emerging Drugs are Gaboxadol, GTX-101, GT-AS/AGIL-AS, and many others.&nbsp;
&nbsp;
Angelman Syndrome&nbsp;Key Players
Angelman Syndrome key players are Ovid Therapeutics, GeneTx Biotherapeutics, PTC Therapeutics, and many others.&nbsp;

Angelman Syndrome Market

Angelman Syndrome Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.